Biomedical Sciences Research Center Alexander Fleming (BSRC Fleming)
Core Data
Hosting Legal Entity
Biomedical Sciences Research Center Alexander Fleming
Fleming 34, Vari-Athens, PO: 16672, Attica (Greece)
Type Of RI
Coordinating Country
Current Status:
Operational since 2005
Being upgraded since 2012 to 2015
Scientific Description
Mission and objectives
Fleming is non-profit research organisation that operates under the supervision of the General Secretariat for Research and Technology of the Hellenic Ministry of Education. It was established in 1998 and today is actively involved in cutting edge research in biomedical sciences. Integral to the Center's research activities are several platforms of genetic permutation in the mouse and their application in human disease modeling. Fleming participates in numerous EC FP6 and FP7 projects using the mouse as a research tool and has extensive interations with the biotech and pharmaceutical industry.Fleming currently consists of 14 highly competitive groups active in the areas of disease modelling, transgenic and conditional mutagenesis in the mouse, post-transcriptional regulation of gene expression, inter- and intra-cellular signalling and functional genomics. The Center is internationally recognized for its projects in translational research, and focuses on pathway, target and biomarker identification and validation, preclinical evaluation of therapeutics in animal models and novel drug development and screening . The Center's major goal is to support excellent research with a focus on innovation. Over the last decade Fleming has established state-of-the-art facilities that offer services for translational research to the Center internally, but also to researchers and companies in Greece and abroad. These include the Animal House (currently Greece's largest), as well as Units for Transgenesis and Cryopreservation, Genomics, Proteomics, Flow cytometry, Histopathology, and BioIT. Fleming has recently been invited to submit a plan for a 3.9Million euro grant to establish a local integrated infrastructure in the context of the ESFRI infrastructure INFRAFRONTIER, named Infrafrontier-GR. Infrafrontier-GR aims to provide an advanced platform for specialised phenotyping of mouse models of disease towards novel target identification and innovative drug development. The Infrastructure will build on the Center's already operating facilities for animal housing, transgenesis, archiving and phenotyping to provide easy access to mouse models and to facilitate their dissemination and exploitation within the Greek research community and abroad. Furthermore, Infrafrontier-GR will provide specialist secondary phenotyping services using advanced technological platforms, initially in the field of immunology and cancer, as well as in other disease areas, and is expected to enhance the discovery and innovation potential of the Greek research and industrial environment. In the context of its technology transfer and innovation activities, in 2006 the Center established a highly successful spin-off company, Biomedcode Hellas SA, a CRO that provides full preclinical drug evaluation services to the pharmaceutical industry using a unique collection of proprietary mouse models of human inflammatory diseases.Fleming costitutes a prime example of regional smart specialisation, achieving high levels of growth based on efficient innovation in areas of excellence and specialisation.

RI Keywords
Cryopreservation, Histopathology, Systems biology, Mouse phenotyping, Proteomics, Flow cytometry, Animal models of disease, Animal house, Genomics, Transgenesis, Translational research
RI Category
Biomedical Imaging Facilities
Bio-informatics Facilities
Systems Biology/Computational Biology Facilities
Genomic, Transcriptomic, Proteomics and Metabolomics Facilities
Animal facilities
Translational Research Centres
Scientific Domain
Biological and Medical Sciences
Archiving and phenotyping services

Fleming, through Infrafrontier-GR, aims to build and operate a state-of-the-art mouse clinic that will include animal housing and phenotyping facilities based on cutting edge technological platforms. The Infrastructure will provide easy access to mouse models and facilitate their dissemination within the Greek research community and abroad. Furthermore, it will provide specialist secondary phenotyping services initially in the field of immunology, as well as in other disease areas and is expected to boost Greek research productivity and innovation potential. Services in secondary phenotyping are specialized and disease-specific and include:  Genomics (gene expression profiling and high throughput technologies, including array-based approaches (e.g. Affymetrix) and next-generation deep sequencing platforms (e.g. Illumina)  Proteomics (mass-spectrometry platforms allowing whole proteome identification)  Imaging (live cell and whole animal imaging capabilities)  Bioinformatics (units specializing in the comprehensive analysis of large experimental data sets)  Histopathology (unit which performs standardized histological assays, pathological evaluation and documentation)  Cytochemistry (units capable of performing flow cytometry-based analysis in large number of samples)  Biochemistry and Toxicology (units suitable to measure wide range of metabolites in biological fluids including blood, urine and tissue extracts)  Pharmacokinetics (units capable of following the metabolic fates of experimental drugs in mice  Evaluation of pharmaceuticals Furthermore the Infrastructure provides state-of-the art archiving and distribution services in accordance with the protocols and standards of the European Mutant Mouse Archive (EMMA), of which Fleming is already a Member. The network will also provide Training on high end technological platforms.